Tag Archives: GSK

It's Industry's Problem: A Fresh Take on R&D Costs

High in-house failure rates are slowing progress on pricing affordability, says GSK CEO Andrew Witty. If there is one message that big pharma has applied consistently over the years, it is that drug development is very expensive. Big bucks and long-term investment in the institutional know-how and capacity built exclusively through private enterprise are what […]
Posted in Global, IP, leadership, R&D | Also tagged , , , | 2 Comments

Study Points to Dramatic Drop In R&D Expenditure

Pharma expenditure on R&D has dropped to an estimated $68 billion, according to Thomson Reuters’ 2011 Pharmaceutical R&D Factbook. The three-year low demonstrates the receding trends of drug success, the amount of drugs entering Phase I and II trials and the number of new molecular entities (NMEs) launched in the global market.
Posted in Global, Guest Blog, R&D | Also tagged , , , | 1 Comment

Lives of Patients Keep Sales Reps off Life Support

Pharm Exec’s sister conferencing unit explores the future of the US sales rep, including the implications of GSK’s new value-based compensation model Last week brought a small but dedicated group of sales professionals to a CBI conference in San Diego with a clear mandate: to rate the future of the “detail man” — dead or […]
Posted in Sales | Also tagged , , , | Leave a comment

Justice to Pharma: "Do the Perp Walk!"

Former GSK counsel is the first target in government’s executive-liability crackdown. Could J&J be next? The US Department of Justice filed criminal charges last week against Lauren Stevens, a former VP and assistant general counsel at GlaxoSmithKline. Going after pharma execs marks a seismic shift in the government’s efforts to stem the tide of fraud […]
Posted in Legal, Strategy | Also tagged , , , , | 4 Comments

Avandia, Pharma, and the New FDA

The Harvard prof who wrote the book on FDA (literally) deconstructs the decision on Avandia—and its future implications. GlaxoSmithKline’s diabetes drug Avandia became mired in such controversy regarding its safety in recent years that it was dubbed “another Vioxx”—exactly what the pharmaceutical industry had vowed never to produce. Two weeks ago, FDA’s decided to restrict […]
Posted in FDA, Regulatory, Safety | Also tagged , , , , | 2 Comments
  • Categories

  • Meta